BAJAJ BROKING

Notification
No new Notification messages
Parmeshwar Metal IPO is Open!
Apply for the Parmeshwar Metal IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Biocon Gets China NMPA Approval for Tacrolimus Capsules

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Biocon Ltd announced its subsidiary’s approval from NMPA China for Tacrolimus capsules. The drug will strengthen its portfolio and bolster its global market presence. Biocon Ltd share price rose by 1.13% post-announcement.

Biocon news today

Biocon Pharma Ltd, a wholly owned subsidiary of Biocon Ltd, has received approval from the National Medical Products Administration (NMPA) in China for its Tacrolimus capsules in strengths of 0.5mg, 1mg, and 5mg. Tacrolimus, an immunosuppressant drug, is primarily used to prevent organ rejection in transplant patients by modulating the immune system.

Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25

BIOCON LIMITED.

Trade

369.25-4.00 (-1.07 %)

Updated - 03 January 2025
377.00day high
DAY HIGH
368.00day low
DAY LOW
2143230
VOLUME (BSE)

Key Takeaways

  • Approval Scope: Tacrolimus capsules approved in 0.5mg, 1mg, and 5mg strengths.

  • Therapeutic Use: Prevents organ rejection in transplant patients.

  • Global Presence: Enhances Biocon’s portfolio in complex drugs.

Also read: Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment

Table: Biocon’s Q2 FY25 Financial Overview

Metric

Q2 FY25

Q2 FY24

Change (YoY)

Net Profit

₹27.1 crore

₹172 crore

-84.2%

Revenue from Operations

₹3,590.4 crore

₹3,462 crore

+3.7%

EBITDA

₹685.5 crore

₹741.3 crore

-7.6%

Strengthening Biocon’s Global Position

This approval marks a strategic milestone for Biocon, as it further strengthens the company’s portfolio of complex drugs and expands its reach in the global pharmaceutical market. With the Chinese market’s regulatory clearance, Biocon can expedite the commercialisation of Tacrolimus capsules in the region.

Impact on Biocon Ltd Share Price

Following the announcement, Biocon Ltd share price increased by 1.13%, closing at ₹372.95 on the BSE. This reflects investor confidence in Biocon’s ongoing efforts to expand its global footprint and enhance its portfolio.

Biocon’s NMPA approval for Tacrolimus capsules demonstrates its commitment to innovation and global expansion. The move further cements Biocon’s position as a leader in the biotechnology and pharmaceutical sectors, with promising prospects for future growth.

Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways

Do you have a trading account app or demat account app?

You can open an account with Bajaj Broking in minutes.

Download the Bajaj Broking app now from Play Store or App Store.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹5300+ Cr MTF Book

icon-with-text